Small Molecule Targeted Drug Research Institute Established
Release time:
2020-08-14
Small Molecule Targeted Drug Research Institute Established
News 9# July 13 On the morning of the 9th, the listing ceremony of Anhui Jianfeng Beika Pharmaceutical Small Molecule Targeted Drug Research Institute was held in the Dongzhi Economic Development Zone of Anhui Province.
Dongzhi County Party Secretary Li Mingyue, County Mayor Sheng Guoxing, Chairman of the Group Company and Chairman of the Pharmaceutical Company Jiang Xiaomeng, and Lu Wei, founder of Shanghai Beika Pharmaceutical Company and professor of the Institute of Medicine of the Chinese Academy of Sciences, jointly unveiled the institute (right picture).
Sheng Guoxing County Chief pointed out in his speech at the listing site that the establishment of Anhui Jianfeng Beika Pharmaceutical Small Molecule Targeted Drug Research Institute is an attempt and exploration to deepen innovation drive and carry out industry-university-research cooperation. He hopes that Jianfeng Group will continue to increase investment in funds and talents, integrate scientific research resources, give full play to the innovative advantages of the research institute, and build the small molecule targeted drug research institute into a research institute with strong academic atmosphere, close industry-university-research cooperation, and remarkable scientific and technological achievements. He asked the Dongzhi Economic Development Zone Management Committee and relevant units directly under the county to make every effort to serve and ensure the construction and operation of the research institute, and through the joint efforts of all parties, the Dongzhi Economic Development Zone will be built into a highland of scientific and technological innovation, so that the park will bloom with science and technology. Flowers, bear the fruit of industry. Jiang Xiaomeng, chairman of
group company, delivered a speech at the listing ceremony of the research institute. He said that Shanghai North Carolina Pharmaceutical Company is a holding subsidiary of Jianfeng Group. It is a high-tech enterprise in Shanghai, a "specialized and new" technology enterprise in Shanghai, and a "Shanghai patent pilot enterprise". It has an academician expert workstation and Songjiang District "Enterprise Technology Center", and has a number of "Shanghai High-tech Achievement Transformation Project" results. The products mainly include intermediates such as small molecule targeted and alkaloid anti-tumor drugs. The company takes Shanghai Beika as the research and development and market highland, and takes Jianfeng Beika Pharmaceutical as the link of technology and variety transformation. The research and development results and industrialization results are produced and sold by two factories of Anhui Xinbeika Chemical and Anhui Zhongwang Pharmaceutical, and a small molecule targeted drug manufacturing base is built in Dongto Economic Development Zone. In order to better develop small molecule targeted drugs, with the assistance of Dongzhi County Party Committee and Economic Development Zone, a small molecule targeted drug research institute was established to speed up the progress of scientific and technological innovation and technological transformation, and realize the industrialization of small molecule targeted drug products as soon as possible. At the same time, the Small Molecule Targeted Drug Research Institute will also rely on the technical support of three academicians and experts of Jianfeng Pharmaceutical and four postdoctoral workstations, and cooperate with the Chinese Academy of Sciences, China Pharmaceutical University, Fudan University, Shanghai Molecular Therapy and New Drug Creation Engineering Technology Research Center and other scientific research institutions to establish long-term industry-university-research cooperation, in accordance with the principle of "innovation, creation, creation" and strive to create "green environmental protection, top technology, for the benefit of human health" high-end scientific research institutions. After the opening ceremony of
, Li Mingyue, Secretary of Dongzhi county Party committee, was interviewed by Jinhua Daily. While congratulating Jianfeng group on the 23rd anniversary of its establishment 60#, he said that Dongzhi county government and relevant departments will give maximum support and service to the small molecule targeted drug research institute, and ensure the construction and operation of the research institute, We hope that the Institute can give full play to its advantages and strive to achieve remarkable results as soon. (Ni Yingzhen Zhang Feifei)
1000 . The structure of small molecule drugs has good spatial dispersion, and its chemical properties determine its good pharmaceutical properties and pharmacokinetic properties. Small molecule drugs are usually signal transduction inhibitors, which can specifically block the signal transduction pathway necessary for tumor growth and proliferation, so as to achieve the purpose of treatment.
Targeting ). The purpose is to target the drug or its carrier at a specific lesion site and to accumulate or release the active ingredient at the target site. Targeted preparations can make the drug form a relatively high concentration in the target area, thereby improving the efficacy of the drug while inhibiting toxic side effects and reducing the damage to normal tissues and cells.
More information
Company fully deploys 2019 work
On January 28, the group company held a business analysis meeting to review and summarize the work situation in 2018, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises made reports on the overall work situation in 2018, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2019. Xiang Chongping, deputy general manager of the group company, made a systematic review of the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the internal control, safety and environmental protection work in 2018. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2018 and made a comparative analysis of the main economic indicators of each industrial sector. In 2018, the operating indicators of the company's various industrial sectors have improved significantly year-on-year, and the group company has also created the best operating performance in history. All units have completed the formulation of the second round of "three-year business plan", which points out the direction for the next three years of business work; the group company has also completed the first draft of the new "five-year strategic development plan", which is being revised and enriched. In addition, the two main businesses have also made substantial progress in investment expansion and industrial integration around strategic objectives, and the operating costs of major enterprises have decreased to varying degrees; the optimization of organizational structure and post setting has achieved new results, and management efficiency and people
2020
07-22
Company fully deploys 2019 work
On January 28, the group company held a business analysis meeting to review and summarize the work situation in 2018, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises made reports on the overall work situation in 2018, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2019. Xiang Chongping, deputy general manager of the group company, made a systematic review of the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the internal control, safety and environmental protection work in 2018. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2018 and made a comparative analysis of the main economic indicators of each industrial sector. In 2018, the operating indicators of the company's various industrial sectors have improved significantly year-on-year, and the group company has also created the best operating performance in history. All units have completed the formulation of the second round of "three-year business plan", which points out the direction for the next three years of business work; the group company has also completed the first draft of the new "five-year strategic development plan", which is being revised and enriched. In addition, the two main businesses have also made substantial progress in investment expansion and industrial integration around strategic objectives, and the operating costs of major enterprises have decreased to varying degrees; the optimization of organizational structure and post setting has achieved new results, and management efficiency and people
2020
07-31
The truth about private equity investments you need to know.
China Securities Regulatory Commission Zhejiang Regulatory Bureau and China Securities Investor Protection Fund Co., Ltd. jointly launched the "those private equity fund investment truth you need to know" investment education products. With the outbreak of private equity investment, the proportion of individual investors has further increased, and there are more and more "rich myth" scams. But the things behind "private placement" may not be as simple as you think, and risk prevention knowledge needs to be known early.
2020
07-31
The truth about private equity investments you need to know.
China Securities Regulatory Commission Zhejiang Regulatory Bureau and China Securities Investor Protection Fund Co., Ltd. jointly launched the "those private equity fund investment truth you need to know" investment education products. With the outbreak of private equity investment, the proportion of individual investors has further increased, and there are more and more "rich myth" scams. But the things behind "private placement" may not be as simple as you think, and risk prevention knowledge needs to be known early.
2020
07-30
The truth about private equity investments you need to know.
China Securities Regulatory Commission Zhejiang Regulatory Bureau and China Securities Investor Protection Fund Co., Ltd. jointly launched the "those private equity fund investment truth you need to know" investment education products. With the outbreak of private equity investment, the proportion of individual investors has further increased, and there are more and more "rich myth" scams. But the things behind "private placement" may not be as simple as you think, and risk prevention knowledge needs to be known early.
2020
07-31
Chairman Jiang Xiaomeng Directs Work in Yunnan Peak
On December 16, Jiang Xiaomeng, Secretary of the Party committee and chairman of the group company, went to Yunnan Jianfeng cement company to investigate and guide the work. On the morning of the same day, accompanied by the Yunnan peak management team, Jiang Xiaomeng went deep into the front line and successively went to the central control room of the production and manufacturing department, the raw material clay yard, the lignite yard and other areas for field investigation and investigation to understand the problems existing in the production and operation process. Subsequently, a business analysis meeting was held to make a comparative analysis of the various business indicators of Yunnan Jianfeng from January to November this year, and put forward two requirements to the management team: further strengthen internal management and improve execution; strengthen the coordination of external relations, and improve The ability and level of enterprise resource acquisition. At the Yunnan Jianfeng middle-level cadre meeting held on the afternoon of the 16th, Jiang Xiaomeng first fully affirmed Yunnan Jianfeng's highest output and best benefits since it was put into production in 2018, and expressed his gratitude to all cadres and employees of Yunnan Jianfeng for their hard work. After that, Jiang Xiaomeng made a detailed analysis of the cement industry and the regional market environment in Yunnan, and combined with the current production and operation situation of Yunnan Jianfeng, put forward the focus of the next step: 1. should fully attach importance to and mobilize the initiative and responsibility of employees at all levels to improve the overall execution of the team; 2. raw material mines are an important factor restricting the future development of cement enterprises, which should be paid full attention to and formulate clear strategies and methods, set out a timetable to obtain future production resources as much as possible; 3. continuously advocate and promote technological innovation, keep pace with the times, continuously improve production management, equipment management, production technology level, and maintain the competitive advantage of the industry; 4. further strengthen production
2020
07-31